Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBR733
- Development stage
- Phase 1
- Lead developer
- Imbioray
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
IBR733 is an off-the-shelf chimeric antigen receptor-modified natural killer (CAR-NK) cell therapy targeting CD33 and CLL1 for the treatment of acute myeloid leukemia (AML). Developed by Imbioray (Hangzhou) Biomedicine in collaboration with Wuxi People's Hospital, this investigational therapy is designed to leverage immunologic cytotoxicity by replacing or supplementing natural killer cells to target leukemic cells expressing CD33 and CLL1. The product is administered intravenously following lymphodepletion and is currently being evaluated in early-phase clinical trials for relapsed/refractory AML[1][2][4][5].
- Other names
- Anti-CD33/CLL1 CAR NK cell therapyIBR733 cell injectionIBR-733 cell injectionIBR 733 cell injection
02
Targets
CLEC12ACD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on IBR733.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBR733.